The U.S. Food and Drug Administration approved on Tuesday Amgen's Bkemv, the first biosimilar to AstraZeneca's rare blood ...
Amgen’s Bkemv is the first interchangeable biosimilar to Soliris to treat certain rare diseases. The treatment of patients ...
May 16 (Reuters) - (This May 16 story has been officially corrected by Amgen to change the pricing estimate in paragraph 4) The U.S. Food and Drug Administration on Thursday granted accelerated ...
Amgen Inc. won US approval for a new drug to treat a particularly aggressive form of advanced lung cancer, providing a badly ...
(RTTNews) - Amgen (AMGN) said that the U.S. Food and Drug Administration approved Imdelltra or tarlatamab-dlle for the treatment ...
FRIDAY, MAY 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat ...
Amgen Inc. (NASDAQ:AMGN) has recently been in the news due to its involvement in the promising obesity drug market. Analysts ...
The FDA has made two approvals this week: the first interchangeable biosimilar of Soliris and another indication for Breyanzi ...
Die Amgen-Anleihe ist handelbar unter der WKN A3K2PR bzw. der ISIN US031162DD92. Die Anleihe wurde am 22.02.2022 emittiert und hat eine Laufzeit bis 22.02.2029. Das Emissionsvolumen betrug bis zu ...
The U.S. Food and Drug Administration on Thursday granted accelerated approval to Amgen’s tarlatamab, a targeted immunotherapy for adults in the advanced stages of hard-to-treat small cell lung ...
FRIDAY, May, 17, 2024 (HealthDay News) -- The U.S. Food and Drug Administration on Thursday approved a new drug to treat patients with an advanced form of deadly lung cancer. Importantly ...